Article: article from journal or magazin.
Innappropriate renin secretion unmasked by captopril (SQ 14 225) in hypertension of chronic renal failure
8092 Pt 1
Captopril (SQ 14 225), an orally active inhibitor of angiotensin-converting enzyme, was given to 7 hypertensive patients with chronic renal failure whose plasma-creatinine ranged from 1.5--7.4 mg/dl; whose plasma-renin activity was normal; whose hypertension was not controlled by previous therapy consisting in 5 patients of three or more antihypertensive drugs; and whose blood-pressures averaged 176/111 +/- 11/3 mm Hg. Inhibition of converting enzyme by oral captopril, 200 mg twice daily, reduced blood-pressure to 156/100 +/- 9/5 mm Hg. 5 patients needed additional treatment by frusemide 40--250 mg/day orally. With this combined regimen the blood-pressure of all patients averaged 126/85 +/- 4/3 mm Hg after 8 +/- 2 weeks of captopril. The drug was well tolerated. These results suggest that inhibition of angiotensin-converting enzyme with or without sodium depletion is an efficient treatment for hypertension associated with chronic renal failure. It appears that although renin levels in patients with this condition may be "normal", they are inappropriate in relation to the subtle degree of sodium retention that occurs with this disorder.
Administration, OralAdult*Angiotensin-Converting Enzyme InhibitorsAntihypertensive Agents/administration & dosage/*therapeutic useBlood Pressure/drug effectsDrug Therapy, CombinationFemaleFurosemide/therapeutic useHumansHypertension, Renal/drug therapy/*etiologyKidney Failure, Chronic/*physiopathologyMaleMiddle AgedProline/administration & dosage/*analogs & derivatives/therapeutic useRenin/*secretionSodium/metabolism
Web of science
Last modification date